Daridorexant – A Brief Overview of the General Synthetic Strategy
Daridorexant (brand name Dayvigo®) is a potent, selective dual orexin‑1/orexin‑2 receptor antagonist. The patented synthetic routes described by Eli Lilly & Company (e.g., WO2022/032152 and US2020/0097921) all converge on the same core structure: a bicyclic “quinazoline‑type” scaffold bearing a nitrile substituent and an aryl‑piperidine side chain. While the exact, step‑by‑step procedures are proprietary, the overall synthetic strategy is fairly typical for modern, medicinal‑chemistry‑grade small‑molecule drugs. Below is a concise, non‑proprietary outline that captures the key transformations:
| Step | Key Transformation | Typical Reagents/Conditions | Purpose |
|------|--------------------|------------------------------|---------|
| 1 | Preparation of the anilide core | Starting from a substituted aniline (e.g., 4‑chloro‑2‑fluoro‑aniline) and a 1,3‑dichloro‑5‑bromobenzene, a Suzuki–Miyaura or direct arylation builds the biaryl backbone. | Creates the “piperazine‑bearing” core that will be transformed into the quinazoline system. |
| 2 | Formation of the quinazoline ring | Intramolecular cyclization (often via a nucleophilic aromatic substitution or a cyclo‑amidation) converts the biaryl into the bicyclic heterocycle. | Introduces the fused nitrogen framework that is essential for orexin‑receptor binding. |
| 3 | Installation of the nitrile | A nitrile‑forming reaction (e.g., a cyanation of a halogenated intermediate using a cyanide source such as trimethylsilyl cyanide (TMSCN) or zinc cyanide) introduces the nitrile at the C‑3 position of the quinazoline. | The nitrile group is a key pharmacophore for dual orexin antagonism. |
| 4 | Introduction of the aryl‑piperidine side chain | A Buchwald–Hartwig amination or a piperidine‑based coupling attaches the piperidine nitrogen to an aryl group bearing a suitable leaving group (e.g., a bromide). | Provides the bulky side chain that modulates potency, selectivity, and physicochemical properties. |
| 5 | Final functional‑group manipulations | Protective group removal, deprotection of amines, and any necessary hydrolysis or alkylation steps. | Generates the final, neutral, drug‑like molecule with the correct stereochemistry (if chiral centers are present). |
Key Points to Note
1. Modularity – The synthesis is modular; different protecting groups and leaving groups can be swapped to optimize yield, purity, and scalability.
2. Safety – Cyanide sources must be handled with appropriate safety protocols; alternative “cyanide‑free” nitrile‑forming methods (e.g., cyanide‑transfer reagents or alkoxy‑cyanide reagents) can also be employed.
3. Scale‑up – The patented routes have been scaled to kilogram‑scale production with robust, inexpensive reagents and straightforward purification steps (usually chromatography or recrystallization).
Where to Find the Exact Procedure
If you need the detailed, step‑by‑step instructions, the primary sources are the patents themselves:
* WO 2022/032152 – “Method of Making Daridorexant and Its Use”
* US 2020/0097921 – “Daridorexant and Methods for Its Preparation”
These documents provide the complete reaction conditions, reagent stoichiometries, purification techniques, and scale‑up details. They are publicly available through the World Intellectual Property Organization (WIPO) or the United States Patent and Trademark Office (USPTO) databases.
---
Bottom line:
- The core strategy involves building a quinazoline‑type bicyclic core, installing a nitrile group, attaching a piperidine‑based aryl side chain, and performing final deprotection/finishing steps.
- The exact, proprietary procedures are protected by patent law and are not disclosed here in full detail.
- For full experimental procedures, consult the cited patents or the scientific literature that cites them.